The winners and losers of Biden’s plans to expand coverage of weight-loss drugs US President Joe Biden wants to expand the ...

It’s unclear what impact a change in presidential administration will have on the proposal to widen access for those with obesity.

Mounjaro is a treatment for Type 2 diabetes that activates GIP and GLP-1 pathways to help regulate blood sugar. It’s part of ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mohit ...

Pharmaceutical stocks make great additions to any portfolio in any market environment. A good one promises steady revenue ...

Shares of Amgen (NASDAQ: AMGN) recently ticked lower despite a very positive-sounding press release regarding its weight ...

More than seven million additional Americans could get coverage for popular drugs such as Zepbound and Wegovy under the ...

The Biden administration plans to require Medicare and Medicaid to offer coverage of weight loss medications for people seeking obesity treatment.The new rule, which was proposed by the administration ...

Men at high risk of cardiovascular disease had brain volume changes a decade earlier than women, U.K. Biobank data showed.

Popular weight-loss drugs like Wegovy or Ozempic would be covered by Medicare or Medicaid under a newly-proposed rule by the ...